Higher values of TFQI are associated with
obesity,
metabolic syndrome, impaired
renal function,
diabetes, and diabetes-related
mortality.[1][2][3][4][5][6][7] In a large population of community-dwelling euthyroid subjects the thyroid feedback quantile-based index predicted all-cause mortality, even after adjustment for other established risk factors and comorbidities.[8]
A cross-sectional study from Spain observed increased prevalence of type 2 diabetes, atrial fibrillation, ischemic heart disease and hypertension in persons with elevated PTFQI.[9]
Serum Concentrations of Adipocyte Fatty Acid-Binding Protein (A-FABP) are significantly correlateted to TFQI, suggesting some form of cross-talk between adipose tissue and HPT axis.[10]
Despite positive association to metabolic syndrome and type 2 allostatic load a large population-based study failed to identify an association to risks of
dyslipidemia and
non-alcoholic fatty liver disease (NAFLD).[14]
^"Schilddrüsenhormonresistenz und Risiko für Diabetes und metabolisches Syndrom". Diabetologie und Stoffwechsel. 14 (2): 78. 16 April 2019.
doi:
10.1055/a-0758-5718.
S2CID243074371.
^Paschou, Stavroula A.; Alexandrides, Theodoros (19 October 2019). "A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture". Hormones. 18 (4): 401–408.
doi:
10.1007/s42000-019-00139-z.
PMID31630372.
S2CID204786351.
^Guan, Haixia (April 2019). "Mild Acquired Thyroid Hormone Resistance Is Associated with Diabetes-Related Morbidity and Mortality in the General Population". Clinical Thyroidology. 31 (4): 138–140.
doi:
10.1089/ct.2019;31.138-140.
S2CID145947179.
^Lou-Bonafonte, José Manuel; Civeira, Fernando; Laclaustra, Martín (20 February 2020). "Quantifying Thyroid Hormone Resistance in Obesity". Obesity Surgery. 30 (6): 2411–2412.
doi:
10.1007/s11695-020-04491-7.
PMID32078724.
S2CID211217245.